Literature DB >> 12558329

Invasive group A streptococcal infections in the San Francisco Bay area, 1989-99.

D J Passaro1, D S Smitht, E C Hett, A L Reingold, P Daily, C A van Beneden, D J Vugia.   

Abstract

To describe the epidemiology of invasive group A streptococcal (iGAS) infections in the San Francisco Bay Area, population-based active surveillance for laboratory-confirmed iGAS was conducted by the California Emerging Infections Program in three California counties. From January 1989 to December 1999, 1415 cases of iGAS were identified. Mean iGAS incidence was 4.06/100,000 person-years and case fatality ratio was 13%, with no linear trends over time. Incidence was lowest in adolescents, was higher in men than women (4.4 vs. 3.2/100,000 person-years), and was higher in African-Americans (6.7) than in non-Hispanic (4.1) or Hispanic (3.4) Whites, Asians (2.2) or Native Americans (17/100,000 person-years). Injecting drug use was the riskiest underlying condition and was associated with the highest attributable risk. Cases were associated with several underlying conditions, but 23% occurred in previously healthy persons. From 1989-1999, iGAS infections in the San Francisco Bay Area became neither more common nor more deadly.

Entities:  

Mesh:

Year:  2002        PMID: 12558329      PMCID: PMC2869908          DOI: 10.1017/s0950268802007823

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  11 in total

1.  Invasive group A streptococcal disease in Alberta, Canada (2000 to 2002).

Authors:  Gregory J Tyrrell; Marguerite Lovgren; Bertha Kress; Karen Grimsrud
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

2.  Clinical and epidemiological aspects of invasive Streptococcus pyogenes infections in Denmark during 2003 and 2004.

Authors:  Bogdan Luca-Harari; Kim Ekelund; Mark van der Linden; Margit Staum-Kaltoft; Anette M Hammerum; Aftab Jasir
Journal:  J Clin Microbiol       Date:  2007-10-24       Impact factor: 5.948

3.  Epidemiology of severe Streptococcus pyogenes disease in Europe.

Authors:  Theresa L Lamagni; Jessica Darenberg; Bogdan Luca-Harari; Tuula Siljander; Androulla Efstratiou; Birgitta Henriques-Normark; Jaana Vuopio-Varkila; Anne Bouvet; Roberta Creti; Kim Ekelund; Maria Koliou; Ralf René Reinert; Angeliki Stathi; Lenka Strakova; Vasilica Ungureanu; Claes Schalén; Aftab Jasir
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

4.  Invasive group A streptococcal infections, clinical manifestations and their predictors, Montreal, 1995-2001.

Authors:  Maria-Graciela Hollm-Delgado; Robert Allard; Pierre A Pilon
Journal:  Emerg Infect Dis       Date:  2005-01       Impact factor: 6.883

5.  Genomic analysis of emm59 group A Streptococcus invasive strains, United States.

Authors:  Nahuel Fittipaldi; Randall J Olsen; Stephen B Beres; Chris Van Beneden; James M Musser
Journal:  Emerg Infect Dis       Date:  2012-04       Impact factor: 6.883

6.  Differences in the epidemiology between paediatric and adult invasive Streptococcus pyogenes infections.

Authors:  L Zachariadou; A Stathi; P T Tassios; A Pangalis; N J Legakis; J Papaparaskevas
Journal:  Epidemiol Infect       Date:  2013-06-07       Impact factor: 4.434

7.  Group A Streptococcal bacteraemia. Experience at King Fahad Medical City in Riyadh, Saudi Arabia.

Authors:  Fawzyh J Al-Khadidi; Mohammed A AlSheheri; Tariq S AlFawaz; Mushira A Enani; Abdulaziz A AlAqeel; Dayel A AlShahrani
Journal:  Saudi Med J       Date:  2017-10       Impact factor: 1.484

8.  Invasive group A streptococcal disease: risk factors for adults.

Authors:  Stephanie H Factor; Orin S Levine; Benjamin Schwartz; Lee H Harrison; Monica M Farley; Allison McGeer; Anne Schuchat
Journal:  Emerg Infect Dis       Date:  2003-08       Impact factor: 6.883

9.  Emerging Infections Program Efforts to Address Health Equity.

Authors:  James L Hadler; Duc J Vugia; Nancy M Bennett; Matthew R Moore
Journal:  Emerg Infect Dis       Date:  2015-09       Impact factor: 6.883

10.  Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks.

Authors:  Tetyana I Vasylyeva; Pavlo Smyrnov; Steffanie Strathdee; Samuel R Friedman
Journal:  J Int AIDS Soc       Date:  2020-07       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.